TrialBritish journal of cancer2021

A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer.

Hee Seung Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.